SAB Biotherapeutics (SABS) Business News Dec. 18, 2025, 13:00 UTC First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D Full text
There are no comments here yet...